188 related articles for article (PubMed ID: 9550942)
1. Endocannabinoids: a new class of vasoactive substances.
Randall MD; Kendall DA
Trends Pharmacol Sci; 1998 Feb; 19(2):55-8. PubMed ID: 9550942
[TBL] [Abstract][Full Text] [Related]
2. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery.
White R; Hiley CR
Br J Pharmacol; 1997 Dec; 122(8):1573-84. PubMed ID: 9422801
[TBL] [Abstract][Full Text] [Related]
3. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation.
Randall MD; Kendall DA
Eur J Pharmacol; 1997 Sep; 335(2-3):205-9. PubMed ID: 9369375
[TBL] [Abstract][Full Text] [Related]
4. An endogenous cannabinoid as an endothelium-derived vasorelaxant.
Randall MD; Alexander SP; Bennett T; Boyd EA; Fry JR; Gardiner SM; Kemp PA; McCulloch AI; Kendall DA
Biochem Biophys Res Commun; 1996 Dec; 229(1):114-20. PubMed ID: 8954092
[TBL] [Abstract][Full Text] [Related]
5. The complexities of the cardiovascular actions of cannabinoids.
Randall MD; Kendall DA; O'Sullivan S
Br J Pharmacol; 2004 May; 142(1):20-6. PubMed ID: 15131000
[TBL] [Abstract][Full Text] [Related]
6. The quest for a vascular endothelial cannabinoid receptor.
Kunos G; Bátkai S; Offertáler L; Mo F; Liu J; Karcher J; Harvey-White J
Chem Phys Lipids; 2002 Dec; 121(1-2):45-56. PubMed ID: 12505689
[TBL] [Abstract][Full Text] [Related]
7. Mesenteric vasodilation mediated by endothelial anandamide receptors.
Wagner JA; Varga K; Járai Z; Kunos G
Hypertension; 1999 Jan; 33(1 Pt 2):429-34. PubMed ID: 9931142
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.
Herradón E; Martín MI; López-Miranda V
Br J Pharmacol; 2007 Nov; 152(5):699-708. PubMed ID: 17704831
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery.
Randall MD; McCulloch AI; Kendall DA
Eur J Pharmacol; 1997 Aug; 333(2-3):191-7. PubMed ID: 9314035
[TBL] [Abstract][Full Text] [Related]
10. Anandamide and endothelium-derived hyperpolarizing factor act via a common vasorelaxant mechanism in rat mesentery.
Randall MD; Kendall DA
Eur J Pharmacol; 1998 Apr; 346(1):51-3. PubMed ID: 9617751
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of cannabinoids.
Randall MD; Harris D; Kendall DA; Ralevic V
Pharmacol Ther; 2002 Aug; 95(2):191-202. PubMed ID: 12182966
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of endocannabinoids--the plot thickens.
Kunos G; Járai Z; Varga K; Liu J; Wang L; Wagner JA
Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):71-84. PubMed ID: 10785543
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries.
O'Sullivan SE; Kendall DA; Randall MD
Br J Pharmacol; 2004 Jun; 142(3):435-42. PubMed ID: 15148250
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoids as cardiovascular modulators.
Kunos G; Járai Z; Bátkai S; Goparaju SK; Ishac EJ; Liu J; Wang L; Wagner JA
Chem Phys Lipids; 2000 Nov; 108(1-2):159-68. PubMed ID: 11106789
[TBL] [Abstract][Full Text] [Related]
15. Effects of hypertension on vasorelaxation to endocannabinoids in vitro.
Wheal AJ; Randall MD
Eur J Pharmacol; 2009 Jan; 603(1-3):79-85. PubMed ID: 19100733
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.
White R; Ho WS; Bottrill FE; Ford WR; Hiley CR
Br J Pharmacol; 2001 Oct; 134(4):921-9. PubMed ID: 11606334
[TBL] [Abstract][Full Text] [Related]
18. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
19. Production and physiological actions of anandamide in the vasculature of the rat kidney.
Deutsch DG; Goligorsky MS; Schmid PC; Krebsbach RJ; Schmid HH; Das SK; Dey SK; Arreaza G; Thorup C; Stefano G; Moore LC
J Clin Invest; 1997 Sep; 100(6):1538-46. PubMed ID: 9294122
[TBL] [Abstract][Full Text] [Related]
20. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
Molina-Holgado F; Molina-Holgado E; Guaza C; Rothwell NJ
J Neurosci Res; 2002 Mar; 67(6):829-36. PubMed ID: 11891798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
